Cargando…

Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample

INTRODUCTION: Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. The aim of PGx testing is to increase therapy efficacy and safety, by applying e.g. dose adjustments in patients with a specific geno- or phenotype. PGx guidelines for psychotropic drugs are avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Lunenburg, C., Ishtiak-Ahmed, K., Thirstrup, J., Gasse, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471865/
http://dx.doi.org/10.1192/j.eurpsy.2021.395
_version_ 1784789177084149760
author Lunenburg, C.
Ishtiak-Ahmed, K.
Thirstrup, J.
Gasse, C.
author_facet Lunenburg, C.
Ishtiak-Ahmed, K.
Thirstrup, J.
Gasse, C.
author_sort Lunenburg, C.
collection PubMed
description INTRODUCTION: Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. The aim of PGx testing is to increase therapy efficacy and safety, by applying e.g. dose adjustments in patients with a specific geno- or phenotype. PGx guidelines for psychotropic drugs are available (PGx drugs), including atomoxetine used in the treatment of attention deficit hyperactivity disorder (ADHD). In Denmark, broad implementation of PGx is currently still low, possibly due to the lack of population-based studies investigating the real-world impact of PGx variability. OBJECTIVES: The aim of this study is to investigate the association of PGx variability (patients’ genotype/phenotype) in users of atomoxetine and different treatment outcomes in a large population-based sample of individuals with ADHD. METHODS: This study will use data of the large Danish population-based iPSYCH case-cohort study sample including information on genetic variants, prescription drug use and outcome data, e.g. psychiatric and somatic hospitalizations and death. The study population comprises all individuals diagnosed with ADHD born 1981-2005 with at least one prescription for atomoxetine between 1995 and 2016. All individuals will be categorized according to their CYP2D6 phenotypes. We will perform Cox regression analysis to estimate the hazard ratios comparing the rates of the different outcomes in people with different phenotypes adjusted for a number of confounding factors. RESULTS: We have identified approximately 20,000 individuals with ADHD, of whom an estimated 10-20% have filled at least one prescription of atomoxetine. CONCLUSIONS: We expect results in the beginning of 2021. DISCLOSURE: We thank the iPSYCH consortium, in specific the iPSYCH PI’s (Merete Nordentoft, Anders Børglum, Preben B. Mortensen, Ole Mors, Thomas Werge and David M. Hougaard). The iPSYCH project is funded by the Lundbeck Foundation Denmark and the universities and un
format Online
Article
Text
id pubmed-9471865
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-94718652022-09-29 Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample Lunenburg, C. Ishtiak-Ahmed, K. Thirstrup, J. Gasse, C. Eur Psychiatry Abstract INTRODUCTION: Pharmacogenetics (PGx) studies genetic variance and related differences in drug outcomes. The aim of PGx testing is to increase therapy efficacy and safety, by applying e.g. dose adjustments in patients with a specific geno- or phenotype. PGx guidelines for psychotropic drugs are available (PGx drugs), including atomoxetine used in the treatment of attention deficit hyperactivity disorder (ADHD). In Denmark, broad implementation of PGx is currently still low, possibly due to the lack of population-based studies investigating the real-world impact of PGx variability. OBJECTIVES: The aim of this study is to investigate the association of PGx variability (patients’ genotype/phenotype) in users of atomoxetine and different treatment outcomes in a large population-based sample of individuals with ADHD. METHODS: This study will use data of the large Danish population-based iPSYCH case-cohort study sample including information on genetic variants, prescription drug use and outcome data, e.g. psychiatric and somatic hospitalizations and death. The study population comprises all individuals diagnosed with ADHD born 1981-2005 with at least one prescription for atomoxetine between 1995 and 2016. All individuals will be categorized according to their CYP2D6 phenotypes. We will perform Cox regression analysis to estimate the hazard ratios comparing the rates of the different outcomes in people with different phenotypes adjusted for a number of confounding factors. RESULTS: We have identified approximately 20,000 individuals with ADHD, of whom an estimated 10-20% have filled at least one prescription of atomoxetine. CONCLUSIONS: We expect results in the beginning of 2021. DISCLOSURE: We thank the iPSYCH consortium, in specific the iPSYCH PI’s (Merete Nordentoft, Anders Børglum, Preben B. Mortensen, Ole Mors, Thomas Werge and David M. Hougaard). The iPSYCH project is funded by the Lundbeck Foundation Denmark and the universities and un Cambridge University Press 2021-08-13 /pmc/articles/PMC9471865/ http://dx.doi.org/10.1192/j.eurpsy.2021.395 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Lunenburg, C.
Ishtiak-Ahmed, K.
Thirstrup, J.
Gasse, C.
Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title_full Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title_fullStr Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title_full_unstemmed Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title_short Pharmacogenetics and adhd treatment outcomes in the danish population-based IPSYCH sample
title_sort pharmacogenetics and adhd treatment outcomes in the danish population-based ipsych sample
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471865/
http://dx.doi.org/10.1192/j.eurpsy.2021.395
work_keys_str_mv AT lunenburgc pharmacogeneticsandadhdtreatmentoutcomesinthedanishpopulationbasedipsychsample
AT ishtiakahmedk pharmacogeneticsandadhdtreatmentoutcomesinthedanishpopulationbasedipsychsample
AT thirstrupj pharmacogeneticsandadhdtreatmentoutcomesinthedanishpopulationbasedipsychsample
AT gassec pharmacogeneticsandadhdtreatmentoutcomesinthedanishpopulationbasedipsychsample